Report: Boston Scientific pauses Lotus Edge heart valve in Europe

October 31, 2016 By Brad Perriello Leave a Comment

Boston Scientific (NYSE:BSX) is reportedly pausing implantations of its next-generation Lotus Edge replacement heart valve in Europe to investigate a locking mechanism issue.

Marlborough, Mass.-based Boston Scientific has implanted about 200 of the Lotus Edge transcatheter aortic valve replacements in Europe, according to Barclays analyst Matthew Taylor, encountering about a 4% rate of “some issues with [the] locking mechanism of the valve.”

“In these cases (incidence rate of ~4%), the device was recaptured and a new valve was implanted with no major adverse events,” Taylor wrote today in a note to investors.

The company pulled Lotus Edge from the market in Europe, where it won CE Mark approval last month, so it can figure out the problem.

“Boston Scientific is initiating a voluntary removal of field inventory of the Lotus Edge valve system. During the initial launch to a limited number of European sites, we received reports that in some cases the device could not be fully locked and therefore the procedure could not be completed. In all cases, patients were successfully treated with a new valve,” the company told MassDevice.com in an emailed statement. “This action does not impact patients who have already been implanted with the device. The company is completing an evaluation to identify the root cause of the issue. Physicians are advised to use the previous generation Lotus valve system, which continues to be available in Europe.”

“BSX does not think that correcting Edge will require a valve redesign, but having made this decision [Oct. 28], cannot answer the question as to when it will be back in the market with precision. It does not anticipate that this will change any timelines or financial guidance including the Reprise trials or launch of Lotus in the U.S,” Taylor wrote.

Yesterday at the annual Transcatheter Cardiovascular Therapies conference in Washington, D.C., Dr. Ian Meredith (who’s slated to replace chief medical officer Dr. Keith Dawkins next year) presented feasibility data on 21 patients treated with the Lotus Edge device, showing 100% technical success, no or only trace paravalvular leakage and a 4.8% stroke rate, a 9.5% rate of new pacemaker implantation and no repeat procedures.

“The company believes it has something very differentiated; it would not comment on pricing strategy but said that looking at major medtech markets where there are three 3 share players that split the market is illustrative. It would be disappointed with 5% to 10% share given the talent and investment that it is putting in the market and expects to be a leader in the [TAVR] space,” Taylor wrote. “Dr. Dawkins noted increased confidence that BSX can be competitive with 2nd-generation valves on pacer rates, driven by changes in technique and technology. Further, BSX outlined plans for its intermediate- and low-risk trials (Reprise IV and V) which will start in 2017; Reprise IV will randomize versus EW’s S3 and Reprise V will go against surgery.”

Supporting regulatory affairs departments to address clinical requirements under new MDR
By Dietmar Falke and Jaap Laufer, Emergo Group The May 25, 2020 MDR deadline is approaching rapidly, and by now many medical device manufacturers are aware that the MDR requires the proactive collection of post-marketing clinical follow-up (PMCF) data. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog… […]
5 tips to raise funding for your medical device
Securing funding can be a long and tedious process, and medical device businesses must work to position themselves as especially attractive to potential investors to maximize success and accelerate the fundraising process. Jon Speer, Greenlight Guru According to Alejandro Cremades, author of The Art of Startup Fundraising, it can take from six to nine months… […]
FDA recognizes latest ISO 14971 as medical device consensus standard
By Mark Leimbeck and Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted Recognized Consensus Standard status to the third edition of the ISO 14071 risk management standard for medical devices and IVD products. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are… […]
Synaptive Medical updates Modus V surgical microscope
Synaptive Medical announced that its U.S. and Canadian Modus V robotic digital microscope now includes updates such as additional 3D visualization and voice-activated control. The Modus V is a robotically controlled digital microscope used as part of Synaptive’s BrightMatter surgical suite designed for less invasive, patient-specific approaches in complex cranial procedures. The Modus V provides similar… […]
New machine can preserve donor livers for 1 week
Researchers in Switzerland have built a perfusion machine that can preserve human livers for transplantation for a week or more, potentially slashing the number of donor livers that must be discarded due to time-related deterioration. Existing perfusion technology can preserve a donor liver for up to 24 hours. The team of surgeons, biologists and engineers… […]
Smiths Medical launches Portex tracheostomy tubes and kits
Smiths Medical this week launched its Portex polyvinyl chloride tracheostomy tube and kit portfolio. The new polyvinyl chloride (PVC) tube portfolio has options for a variety of patients, according to the company. “Our goal was to create tracheostomy tubes and kits designed to help clinicians provide the best patient care. We’re excited to offer a variety… […]
FDA clears Cleveland Clinic 3D-printed airway stents
The FDA recently cleared 3D-printed, patient-specific stents developed by a doctor at the Cleveland Clinic. Cleveland Clinic physician Tom Gildea developed the stents to keep open the airways of patients with serious breathing disorders caused by inflammation, trauma, tumors and other masses. Airway stents come in a limited number of sizes and shapes and are… […]
Boston Scientific shares drop on Q4 sales news
Shares in Boston Scientific (NYSE:BSX) dropped 8% this morning on news of disappointing fourth-quarter sales. The company’s preliminary earnings report showed sales for the quarter ended Dec. 31, 2019 coming in at $2.9 billion, below the $2.91 billion that analysts were expecting. The unaudited sales figure represents organic growth of 7.3%, missing the company’s own guidance of… […]
Study: Timing for knee replacement surgeries is off
New research from Northwestern Medicine suggests that patients with knee osteoarthritis are having knee surgery at the wrong time. According to the researchers, 90% of patients who could benefit from knee replacement surgery are waiting too long to have it and 25% of patients who don’t need it are having it prematurely. “People are waiting… […]
TransEnterix wants to use more AI in surgical robotics: Here’s how
TransEnterix (NYSE:TRXC) has filed a 510(k) submission to add an artificial intelligence feature to its robot-assisted surgery system in which the system can automatically move the camera for a surgeon. Surgeons have been able to move the camera on TransEnterix’s Senhance System via eye sensing. But the new Intelligent Surgical Unit would allow a surgeon, for… […]
Diversified Plastics names Kieval to board
Diversified Plastics, a custom plastic-injection molder and digital thermoplastic components manufacturer, said today that it has appointed Robert Kieval to its board of directors. Kieval has more than 25 years of experience at all levels of the medtech industry. The CEO of IMMR, Inc., Kieval previously served as chief scientific and clinical officer at women’s… […]